HRP20140634T1 - Farmaceutske otopine, postupak priprave i terapeutske upotrebe - Google Patents
Farmaceutske otopine, postupak priprave i terapeutske upotrebe Download PDFInfo
- Publication number
- HRP20140634T1 HRP20140634T1 HRP20140634AT HRP20140634T HRP20140634T1 HR P20140634 T1 HRP20140634 T1 HR P20140634T1 HR P20140634A T HRP20140634A T HR P20140634AT HR P20140634 T HRP20140634 T HR P20140634T HR P20140634 T1 HRP20140634 T1 HR P20140634T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- solution
- therapeutic uses
- pharmaceutical solutions
- per
- Prior art date
Links
- 239000003186 pharmaceutical solution Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 3
- 229940102223 injectable solution Drugs 0.000 claims 2
- 229940100688 oral solution Drugs 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Claims (6)
1. Stabilna otopina farmaceutskog spoja koji je (2S)-2-{{4R)-2-okso-4-propil-pirolidin-1-il}}butanamid, naznačena time da ima pH vrijednost od između 4.5 i 6.5.
2. Otopina prema patentnom zahtjevu 1, naznačena time da su pH vrijednost između 5.0 i 6.0.
3. Otopina prema patentnom zahtjevu 1, naznačena time da je injektabilna otopina, pri čemu je količina farmaceutskog spoja u rasponu od 0.01 mg po ml do 200 mg po ml.
4. Otopina prema patentnom zahtjevu 1, naznačena time da je oralna otopina, pri čemu je količina farmaceutskog spoja u rasponu od 0.01 mg po ml do 100 mg po ml.
5. Otopina prema patentnom zahtjevu 1, naznačena time da je injektabilna otopina koja ima pH vrijednost od 5.5 ± 0.2.
6. Otopina prema patentnom zahtjevu 1, naznačena time da je oralna otopina koja ima pH vrijednost od 5.5 ±0.2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08003915 | 2008-03-03 | ||
| PCT/EP2009/052454 WO2009109547A1 (en) | 2008-03-03 | 2009-03-02 | Pharmaceutical solutions, process of preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140634T1 true HRP20140634T1 (hr) | 2014-11-21 |
Family
ID=39643757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140634AT HRP20140634T1 (hr) | 2008-03-03 | 2014-07-03 | Farmaceutske otopine, postupak priprave i terapeutske upotrebe |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20110021786A1 (hr) |
| EP (1) | EP2273975B8 (hr) |
| JP (6) | JP2011513360A (hr) |
| KR (1) | KR101353425B1 (hr) |
| CN (1) | CN101945647B (hr) |
| AU (1) | AU2009221177B2 (hr) |
| BR (1) | BRPI0908421C1 (hr) |
| CA (1) | CA2715685C (hr) |
| CY (1) | CY1115254T1 (hr) |
| DK (1) | DK2273975T3 (hr) |
| EA (1) | EA018736B1 (hr) |
| ES (1) | ES2474945T3 (hr) |
| HK (1) | HK1148202A1 (hr) |
| HR (1) | HRP20140634T1 (hr) |
| IL (1) | IL207558A (hr) |
| MX (1) | MX2010009222A (hr) |
| PL (1) | PL2273975T3 (hr) |
| PT (1) | PT2273975E (hr) |
| RS (1) | RS53418B (hr) |
| SI (1) | SI2273975T1 (hr) |
| WO (1) | WO2009109547A1 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53418B (en) * | 2008-03-03 | 2014-12-31 | Ucb Pharma S.A. | PHARMACEUTICALS, ACTION PROCESSING AND THERAPEUTIC USES |
| CN102227217A (zh) * | 2008-10-16 | 2011-10-26 | 约翰斯.霍普金斯大学 | 改善认知功能的方法和组合物 |
| TWI577680B (zh) | 2008-10-22 | 2017-04-11 | 亞雷生物製藥股份有限公司 | 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物 |
| JP5954889B2 (ja) | 2008-11-18 | 2016-07-20 | ユセベ ファルマ ソシエテ アノニム | ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤 |
| RS54692B1 (en) | 2011-12-16 | 2016-08-31 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | PHARMACEUTICAL COMPOSITION COVERING (S) -2- (OXOPYROLIDIN-1-IL) BUTANAMIDE |
| CN102525900A (zh) * | 2012-01-19 | 2012-07-04 | 南京恒道医药科技有限公司 | 左乙拉西坦注射液及其制备方法 |
| CA2864740A1 (en) * | 2012-04-19 | 2013-10-24 | C.R. Bard, Inc. | Infusates with enhanced ph stability under ethylene oxide sterilization |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2014144801A1 (en) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Methods and compositions for improving cognitive function |
| CN103550143B (zh) * | 2013-10-19 | 2019-05-14 | 浙江华海药业股份有限公司 | 一种左乙拉西坦注射液的制备方法 |
| US10925834B2 (en) | 2015-05-22 | 2021-02-23 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
| JP7061602B2 (ja) * | 2016-04-04 | 2022-04-28 | ロクソ オンコロジー， インコーポレイテッド | （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）－ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの液体製剤 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| DK3458456T3 (da) | 2016-05-18 | 2020-12-14 | Array Biopharma Inc | Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid |
| CN106491523A (zh) * | 2016-09-24 | 2017-03-15 | 北京万全德众医药生物技术有限公司 | 一种布瓦西坦口服溶液及其制备方法 |
| US20210161808A1 (en) * | 2018-07-24 | 2021-06-03 | Zenvision Pharma Llp | Nasal Drug Delivery System of Brivaracetam or Salt Thereof |
| WO2020089826A1 (en) * | 2018-11-02 | 2020-05-07 | Zenvision Pharma Llp | Ready to use intravenous infusion of brivaracetam or salt thereof |
| WO2020196306A1 (ja) | 2019-03-28 | 2020-10-01 | 東洋紡株式会社 | 反射防止用円偏光板およびそれを用いた画像表示装置 |
| CN113908120A (zh) * | 2021-09-30 | 2022-01-11 | 北京诺康达医药科技股份有限公司 | 布立西坦药物溶液及其制备方法 |
| CN114213306A (zh) * | 2021-12-28 | 2022-03-22 | 海南鑫开源医药科技有限公司 | 一种布瓦西坦酸杂质的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| WO2005121082A1 (en) * | 2004-06-11 | 2005-12-22 | Ucb, S.A. | Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation |
| EP1731149A1 (en) * | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
| RS53418B (en) * | 2008-03-03 | 2014-12-31 | Ucb Pharma S.A. | PHARMACEUTICALS, ACTION PROCESSING AND THERAPEUTIC USES |
| KR101286540B1 (ko) * | 2008-04-16 | 2013-07-17 | 엘지디스플레이 주식회사 | 액정표시장치 |
-
2009
- 2009-03-02 RS RS20140362A patent/RS53418B/en unknown
- 2009-03-02 EA EA201001402A patent/EA018736B1/ru unknown
- 2009-03-02 BR BRPI0908421A patent/BRPI0908421C1/pt active IP Right Grant
- 2009-03-02 MX MX2010009222A patent/MX2010009222A/es active IP Right Grant
- 2009-03-02 US US12/920,524 patent/US20110021786A1/en not_active Abandoned
- 2009-03-02 CN CN2009801048128A patent/CN101945647B/zh active Active
- 2009-03-02 CA CA2715685A patent/CA2715685C/en active Active
- 2009-03-02 PT PT97163042T patent/PT2273975E/pt unknown
- 2009-03-02 JP JP2010549117A patent/JP2011513360A/ja active Pending
- 2009-03-02 AU AU2009221177A patent/AU2009221177B2/en active Active
- 2009-03-02 PL PL09716304T patent/PL2273975T3/pl unknown
- 2009-03-02 EP EP09716304.2A patent/EP2273975B8/en not_active Revoked
- 2009-03-02 DK DK09716304.2T patent/DK2273975T3/da active
- 2009-03-02 KR KR1020107022027A patent/KR101353425B1/ko active IP Right Grant
- 2009-03-02 SI SI200930971T patent/SI2273975T1/sl unknown
- 2009-03-02 ES ES09716304.2T patent/ES2474945T3/es active Active
- 2009-03-02 WO PCT/EP2009/052454 patent/WO2009109547A1/en active Application Filing
-
2010
- 2010-08-12 IL IL207558A patent/IL207558A/en active IP Right Grant
-
2011
- 2011-03-08 HK HK11102314.2A patent/HK1148202A1/xx unknown
-
2014
- 2014-07-03 HR HRP20140634AT patent/HRP20140634T1/hr unknown
- 2014-07-08 CY CY20141100513T patent/CY1115254T1/el unknown
-
2015
- 2015-03-11 JP JP2015048848A patent/JP2015145382A/ja active Pending
-
2017
- 2017-02-17 JP JP2017027658A patent/JP2017114890A/ja active Pending
-
2019
- 2019-02-21 JP JP2019029289A patent/JP2019089837A/ja active Pending
-
2020
- 2020-04-20 JP JP2020074977A patent/JP2020128384A/ja active Pending
-
2022
- 2022-08-29 JP JP2022135872A patent/JP2022169734A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140634T1 (hr) | Farmaceutske otopine, postupak priprave i terapeutske upotrebe | |
| HRP20201243T1 (hr) | N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala | |
| ATE510537T1 (de) | Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit | |
| NZ597260A (en) | Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone | |
| RU2011109884A (ru) | Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий | |
| HK1149258A1 (en) | Compounds | |
| HRP20240168T1 (hr) | Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije | |
| EP3192506A3 (en) | Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative or 5-aminolevulinic acid as active ingredient | |
| MX2009000722A (es) | Composiciones liquidas de acetato de calcio. | |
| IL192670A (en) | Carboxylic Acids of 1, 3-Dioxane, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
| UA96156C2 (ru) | Эфиры докозагексаеновой кислоты и их применение для лечения и предупреждения сердечнососудистого заболевания | |
| WO2006060681A3 (en) | Pharmaceutical composition containing an anti-nucleating agent | |
| HRP20161295T1 (hr) | Primjena antitumorskog sredstva | |
| EP3228311A3 (en) | Pharmaceutical and nutraceutical compositions of abscisic acid | |
| HRP20150120T1 (hr) | Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam | |
| WO2008008592A3 (en) | Multi-particulate formulation having tramadol in immediate and controlled release form | |
| NO20084478L (no) | Konjugerte lipidderivater | |
| EP1968606A4 (en) | PREPARATION OF PHARMACEUTICAL SALTS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC ACID | |
| WO2008075320A3 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
| MY149863A (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| NZ599271A (en) | Pharmaceutical compositions of rhein or diacerein | |
| AU2012382949A8 (en) | Compositions and methods for treatment of neuropsychological deficits | |
| UA102111C2 (uk) | Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі | |
| GR1006148B (el) | Αναβραζοντα δισκια και αναβραζοντα κοκκια που περιεχουν τρυγικη καρνιτινη |